

# Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

## 1 Guideline

Asthma: The management of asthma

## 2 List of modelling questions

<b>Review questions by scope area</b>	<b>What is the most clinically and cost effective drug (class or combination of drug classes) for the management of children, young people and adults with asthma who are currently taking an optimal single preventer (see previous question) when this fails to provide adequate control?</b>
Population	Adults ( $\geq 16$ years) with a clinician diagnosis of asthma who are uncontrolled on an optimal first line preventer (low dose ICS) and have never been prescribed second line preventer medication.
Interventions and comparators considered for inclusion	<ul style="list-style-type: none"> <li>• Continuing on 'low dose' ICS</li> <li>• Regular 'moderate dose' ICS</li> <li>• Regular 'high dose' ICS</li> <li>• ICS+LABA with SABA as reliever medication</li> <li>• ICS+LABA (formoterol) used as maintenance and reliever therapy (e.g. SMART or MART therapy)</li> <li>• ICS + LAMA (tiotropium)</li> <li>• Leukotriene receptor antagonist +/- ICS</li> <li>• Theophylline or aminophylline +/- ICS</li> <li>• Cromolyns +/- ICS</li> </ul>
Perspective	NHS/PSS
Outcomes	QALYs
Type of analysis	CUA
Issues to note	Children and young people (under 16) were not modelled due to lack of data.